DE QUERIAN SYNOVITIS

DEQUERVAINS TENOSYNOVITIS

De Quervain's tenosynovitis is caused by stenosing tenosynovitis of the first dorsal compartment of the wrist.

The first dorsal compartment at the wrist includes the tendons of the abductor pollicis longus (APL) and the extensor pollicis brevis (EPB).

 

Patients with this condition usually report pain at the dorsolateral aspect of the wrist, with referral of pain toward the thumb and/or the lateral forearm.

This condition responds well to nonsurgical treatment.

PATHOPHYSIOLOGY

In the first dorsal compartment of the wrist, a tendon sheath encloses the abductor pollicis longus and the extensor pollicis brevis tendons at the lateral border of the anatomical snuffbox.

 

Inflammation at this site commonly is seen in patients who use their hands and thumbs in a repetitive fashion. Thus, de Quervain's tenosynovitis can result from cumulative (repetitive) microtrauma. Inflammation also may occur after an isolated episode of acute trauma to the site.

FREQUENCY

De Quervain's tenosynovitis is relatively prevalent, especially among individuals who perform repetitive activities using their hands (eg, certain assembly line workers, secretaries).

MORTALITY/MORBIDITY

Mortality is not associated with de Quervain's tenosynovitis. Some morbidity may result as the patient experiences progressive pain, with limitations occurring in activities requiring use of the affected hand.

SEX

Although this condition is commonly seen in females and males, the incidence of de Quervain's tenosynovitis appears to be significantly greater in women.

Some sources even quote a female-to-male ratio as high as 8:1. Interestingly, many women suffer from de Quervain's tenosynovitis during pregnancy or the postpartum period.

AGE

De Quervain's tenosynovitis is much more common in adults than in children.

CLINICAL

HISTORY

Patients with de Quervain's tenosynovitis typically report localized pain at the dorsolateral aspect of the wrist.

PHYSICAL

The most classic finding in de Quervain's tenosynovitis is a positive Finkelstein test.

CAUSES

Minor cumulative (ie, repetitive) trauma commonly contributes to the development of de Quervain's tenosynovitis.

Activities that may cause repetitive trauma to the wrist include factory work, secretarial duties, golfing, or racket sport playing.

Isolated acute trauma also may contribute to the development of de Quervain's tenosynovitis. In addition, the disorder may occur in association with rheumatoid arthritis.

DIAGNOSIS

LABORATORY STUDIES

IMAGING STUDIES

TREATMENT

PHYSICAL THERAPY

Various forms of physical therapy (PT) or occupational therapy (OT) may be used in the treatment of patients with de Quervain's tenosynovitis. In the acute stage, the therapist may use cryotherapy (eg, cold packs, ice massage) to reduce the inflammation and edema.

Local inflammation also can be treated with topical corticosteroids (eg, hydrocortisone), which are driven into the subcutaneous tissues using ultrasonography (ie, phonophoresis) or electrically charged ions (ie, iontophoresis).

PT or OT also may be indicated for individuals who have undergone surgical correction at the first dorsal compartment.

Once the patient has recovered, the goals of therapy are to strengthen and regain range of motion (ROM) at the thumb, hand, and wrist.

OCCUPATIONAL THERAPY

An occupational therapist can perform an assessment of a patient's activities of daily living (ADL) to help determine possible precipitating factors in the development of de Quervain's syndrome; he/she can then suggest activity modifications.

Although off-the-shelf orthotic devices usually are adequate, sometimes a custom-made thumb spica can be fabricated by a trained occupational therapist.

SURGICAL INTERVENTION

For severe, unresponsive cases of de Quervain's tenosynovitis in which injections, splinting, and ergonomic modification of activities have failed, a referral for surgical treatment to decompress the first dorsal compartment is needed.

OTHER TREATMENT

Using a thumb spica splint or performing local corticosteroid injection can be very effective in treating de Quervain's tenosynovitis.

Several potential complications of injection must be taken into account. They include the following:

MEDICATION

Medications for de Quervain's tenosynovitis serve primarily to decrease pain and inflammation. The most commonly used agents are oral nonsteroidal anti-inflammatory drugs and focally injected corticosteroid medication; these are employed in conjunction with the rest of the rehabilitation plan.

NONSTEROIDAL ANTI-INFLAMMATORY DRUGS

Oral NSAIDs may decrease pain and inflammation in de Quervain's tenosynovitis. Various oral NSAIDs may be used, although, none holds a clear distinction as the drug of choice.

The choice of NSAID is largely a matter of convenience (eg, how frequently doses must be taken to achieve adequate analgesic and anti-inflammatory effects) and cost. Many NSAIDs are available either with or without a prescription.  

IBUPROFEN (Motrin, Advil, Nuprin, Rufen)

DOC for patients with mild to moderate pain. Ibuprofen inhibits inflammatory reactions and pain, possibly by decreasing prostaglandin synthesis.

Adult: 200-800 mg PO tid/qid

Pediatric:

<6 months: Not established

6 months to 12 years: 4-10 mg/kg/dose PO tid/qid

>12 years: Administer as in adults

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Avoid coadministration of other NSAIDs to minimize side effects; special caution in patients on anticoagulants or systemic corticosteroids, with bleeding disorder, or significant alcohol use; avoid during third trimester of pregnancy (potential risk of affecting closure of ductus arteriosus); caution in patients with history of GI bleed, hypertension, CHF, and in elderly patients; please see manufacturer's product information for further details

CORTICOSTEROIDS

In contrast with the widespread systemic distribution of an oral anti-inflammatory drug, a local corticosteroid injection can achieve focal placement of a potent anti-inflammatory agent at the site of maximal tenderness or inflammation.

A variety of corticosteroid preparations are available. Mix the corticosteroid with a local anesthetic agent prior to injection. 

METHYLPREDNISOLONE (Depo-Medrol)

Decreases inflammation by suppressing the migration of polymorphonuclear leukocytes and by reversing increased capillary permeability.

Adult:

20-40 mg of methylprednisolone intralesionally, either 0.5 or 1 mL, respectively, of 40 mg/mL solution; may be mixed with a few mL of lidocaine or other local anesthetics.